Zosano Pharma Corp
Zosano Pharma Corp (ZSAN): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.1 months
D/E 0.88 · 0% dilution
Lead: BLA Filed
1 candidate
N/A
N/A
A transparent, data-derived signal for Zosano Pharma Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.0M
Quarterly Burn
$8.5M
Runway
5.1 mo
Revenue
$132K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| m207 | BLA Filed |
Frequently asked questions
How many drug candidates are in Zosano Pharma Corp's pipeline?
Zosano Pharma Corp (ZSAN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zosano Pharma Corp's lead drug candidate?
Zosano Pharma Corp's most advanced tracked candidate is m207 (BLA Filed) for Migraine.
What is Zosano Pharma Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zosano Pharma Corp has approximately 5.1 months of cash runway.
Who is the CEO of Zosano Pharma Corp?
Directors Steven Lo is the chief executive officer of Zosano Pharma Corp (ZSAN).
Get the full picture on Zosano Pharma Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.